​

Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GILD Stock Forecast

Gilead Sciences (GILD) stock forecast, based on 57 Wall Street analysts, predicts a 12-month average price target of $129.17, with a high of $143.00 and a low of $108.00. This represents a 9.58% increase from the last price of $117.88.

$60 $77 $94 $111 $128 $145 High: $143 Avg: $129.17 Low: $108 Last Closed Price: $117.88

GILD Stock Rating

Gilead Sciences stock's rating consensus is Buy, based on 57 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 35 Buy (61.40%), 21 Hold (36.84%), 1 Sell (1.75%), and 0 Strong Sell (0.00%).

Buy
Total 57 1 21 35 Strong Sell Sell Hold Buy Strong Buy

GILD Price Target Upside V Benchmarks

TypeNameUpside
StockGilead Sciences9.58%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks10.23%

Price Target Trends

1M3M12M
# Anlaysts2513
Avg Price Target$137.50$132.20$123.92
Last Closing Price$117.88$117.88$117.88
Upside/Downside16.64%12.15%5.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 254168--28
Sep, 254168--28
Aug, 2531610--29
Jul, 2531511--29
Jun, 2541511--30
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 09, 2025Carter GouldCantor Fitzgerald$135.00$118.2514.16%14.52%
Oct 06, 2025Wells Fargo$140.00$112.6924.23%18.76%
Aug 11, 2025James ShinDeutsche Bank$135.00$118.8313.61%14.52%
Aug 08, 2025Brian SkorneyRobert W. Baird$108.00$119.41-9.56%-8.38%
Aug 08, 2025Terence FlynnMorgan Stanley$143.00$119.4119.76%21.31%
Jul 14, 2025David RisingerLeerink Partners$114.00$112.091.70%-3.29%
Jun 18, 2025Terence FlynnMorgan Stanley$135.00$108.0025.00%14.52%
Apr 22, 2025Carter GouldCantor Fitzgerald$125.00$105.5118.47%6.04%
Mar 11, 2025Terence FlynnMorgan Stanley$130.00$114.4313.61%10.28%
Mar 05, 2025Johnson Rice$126.00$115.449.15%6.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2025Cowen & Co.BuyBuyhold
Oct 22, 2025RBC CapitalSector PerformSector Performhold
Oct 09, 2025Cantor FitzgeraldOverweightOverweighthold
Oct 08, 2025CitigroupBuyBuyhold
Aug 11, 2025Deutsche BankBuyBuyhold
Aug 08, 2025Cowen & Co.BuyBuyhold
Aug 08, 2025Morgan StanleyOverweightOverweighthold
Aug 08, 2025UBSNeutralNeutralhold
Apr 22, 2025Cantor FitzgeraldNeutralOverweightupgrade
Mar 26, 2025CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$0 $2 $4 $6 $8 $10 $11 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.07$4.96$3.66$4.54$0.38----
Avg Forecast$6.95$8.20$7.10$6.75$4.38$7.59$7.95$8.47$9.07
High Forecast$7.22$8.53$7.42$7.05$4.72$8.42$9.84$10.05$9.61
Low Forecast$6.74$7.96$6.84$6.58$3.87$6.40$5.77$5.94$8.66
Surprise %-98.99%-39.51%-48.45%-32.74%-91.32%----

Revenue Forecast

$24B $26B $28B $30B $32B $34B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.69B$27.30B$27.28B$27.12B$28.75B----
Avg Forecast$24.37B$26.67B$26.53B$27.10B$28.32B$28.49B$29.34B$30.74B$32.22B
High Forecast$25.12B$27.48B$27.44B$27.28B$28.60B$29.85B$29.36B$30.85B$33.68B
Low Forecast$23.80B$26.05B$25.78B$26.91B$28.10B$27.87B$29.31B$30.63B$31.10B
Surprise %1.30%2.38%2.84%0.06%1.54%----

Net Income Forecast

$-5B $-1B $3B $7B $11B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$89.00M$6.22B$4.59B$5.67B$480.00M----
Avg Forecast$-826.75M$5.09B$3.23B$5.67B$5.40B$9.33B$7.55B$8.20B$11.41B
High Forecast$656.68M$6.10B$3.88B$6.80B$5.94B$10.60B$12.37B$12.64B$12.09B
Low Forecast$-2.31B$4.07B$2.58B$4.53B$4.87B$8.06B$7.26B$7.47B$10.90B
Surprise %-110.77%22.36%42.16%--91.12%----

GILD Forecast FAQ

Is Gilead Sciences stock a buy?

Gilead Sciences stock has a consensus rating of Buy, based on 57 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 35 Buy, 21 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Gilead Sciences is a favorable investment for most analysts.

What is Gilead Sciences's price target?

Gilead Sciences's price target, set by 57 Wall Street analysts, averages $129.17 over the next 12 months. The price target range spans from $108 at the low end to $143 at the high end, suggesting a potential 9.58% change from the previous closing price of $117.88.

How does Gilead Sciences stock forecast compare to its benchmarks?

Gilead Sciences's stock forecast shows a 9.58% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (10.23%).

What is the breakdown of analyst ratings for Gilead Sciences over the past three months?

  • October 2025: 14.29% Strong Buy, 57.14% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 14.29% Strong Buy, 57.14% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 10.34% Strong Buy, 55.17% Buy, 34.48% Hold, 0% Sell, 0% Strong Sell.

What is Gilead Sciences’s EPS forecast?

Gilead Sciences's average annual EPS forecast for its fiscal year ending in December 2025 is $7.59, marking a 1897.37% increase from the reported $0.38 in 2024. Estimates for the following years are $7.95 in 2026, $8.47 in 2027, and $9.07 in 2028.

What is Gilead Sciences’s revenue forecast?

Gilead Sciences's average annual revenue forecast for its fiscal year ending in December 2025 is $28.49B, reflecting a -0.91% decrease from the reported $28.75B in 2024. The forecast for 2026 is $29.34B, followed by $30.74B for 2027, and $32.22B for 2028.

What is Gilead Sciences’s net income forecast?

Gilead Sciences's net income forecast for the fiscal year ending in December 2025 stands at $9.33B, representing an 1842.97% increase from the reported $480M in 2024. Projections indicate $7.55B in 2026, $8.2B in 2027, and $11.41B in 2028.